AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Onconetix Stock Soars 10.24% on Nasdaq Listing Relief
Generated by AI AgentAinvest Pre-Market Radar
Wednesday, Jun 18, 2025 7:23 am ET1min read
Onconetix's stock surged by 10.24% in pre-market trading on June 18, 2025, marking a significant rise for the biotech company.
Onconetix has secured continued listing on the Nasdaq exchange following a favorable decision from the Nasdaq Hearings Panel. The company must meet specific compliance requirements by June 13, 2025, to maintain its listing status. This decision comes as a relief for
, which has been focusing on men's health and innovations.The Nasdaq Hearings Panel's approval allows Onconetix to continue its operations without the threat of delisting. The company has completed a 1-for-85 reverse stock split to meet the listing requirements, demonstrating its commitment to compliance and transparency.
This positive development is expected to boost investor confidence in Onconetix, as the company continues to innovate in the biotech sector. The continued listing on Nasdaq provides Onconetix with the platform to attract more investors and expand its market presence.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Serve Robotics Surges 5.16% as Trump Admin Boosts Robotics Push, Eyes 10X Revenue by 2026
Dec.12 2025
New Pacific Metals (NPM) Soars 7.98% as Base Metals Market Anticipates Supply/Demand Shifts
Dec.12 2025
Gevo Inc. (GEVO) Surges 6.22% on $26M BioRecro Partnership to Expand Carbon Management Capabilities
Dec.12 2025
Sable Offshore Soars 5.82% as Private Placement and Policy Tailwinds Drive Pre-Market Rally
Dec.12 2025
Mastercard Inc. Surges 4.55% as Fintech Optimism and AI Expansion Drive Pre-Market Rally
Dec.12 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet